Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Only about 5% of people with type 2 diabetes will achieve remission. A new study has found a combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet provides higher rates ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...

A groundbreaking medication capable of preventing type 2 diabetes by up to 85% is offering new hope to those at risk, a breakthrough highlighted by Al-Ahli Hospital doctors. Endocrinology ...